Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design
Justin T. Matulay(Levine Cancer Institute), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Patrick J. Hensley(University of Kentucky), H. Barton Grossman(The University of Texas MD Anderson Cancer Center), Roger Li(Unknown), Nathan A. Brooks(Eli Lilly (United States)), Neema Navai(The University of Texas MD Anderson Cancer Center), Vikram M. Narayan(Emory University), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 70
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
|Nature Reviews Urology|2022|196
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190